RxDoctor Payments Data

David Hulbert, MD

Family Medicine · Eagle, IDNPI 1730313586

Payments from drug & device makers

$2,174in general payments, 2019–2025

Across 93 payments — averaging $23.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$421
  • Pfizer$311
  • Dexcom, Inc.$258
  • Novo Nordisk$122
  • Tandem Diabetes Care, Inc.$102
  • Amgen$94
  • plus $867 from 27 others

What the payments were for

  • Food & beverage$2,174100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,174 in reported general payments places this provider in the 85th percentile of 803 family medicine providers in Idaho.

See all family medicine providers in Idaho

Medicare billing

Part B allowed, 2024
$115,546
Medicare patients
269
Services billed
1,513

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban85$104,505
Trelegy ElliptaFluticasone/Umeclidin/Vilanter90$85,775
OzempicSemaglutide45$52,617
XareltoRivaroxaban23$39,070
TrulicityDulaglutide29$38,022
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$13,661
Omeprazole355$5,786
Atorvastatin Calcium498$5,194
Losartan Potassium364$3,875
Lantus SolostarInsulin Glargine,hum.Rec.Anlog26$3,541
Gabapentin112$3,503
Celecoxib61$3,330
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen124$3,055
Levothyroxine Sodium306$3,030
HumalogInsulin Lispro16$2,535

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$311$104,50585 claims
GSKTrelegy Ellipta$421$85,77590 claims
Novo NordiskOzempic$122$52,61745 claims
Lilly USA, LLCTrulicity, Humalog$50$40,55745 claims
Johnson & JohnsonXarelto$37$39,07023 claims
AbbVieSynthroid$49$1,49723 claims
Sanofi-aventis U.S. LLCLantus$33$1,14216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 803 family medicine providers in Idaho.

Other family medicine in Eagle

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →